Scarica l'app Stockscreener
17.21
5.13%
0.84
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trevi Therapeutics Inc (TRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trevi Therapeutics stock hits all-time high at 16.13 USD By Investing.com - Investing.com Nigeria
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trevi Therapeutics Announces Upcoming June and July Event Schedule - Yahoo Finance
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
TRVI Q1 2026 Earnings: Clinical Progress Drives Stock Gains Despite EPS MissEarnings Call Q&A - newsline.com
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - AOL.com
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
TRVI Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineProfit Growth Outlook - newsline.com
Trevi Therapeutics (TRVI) Holds Near Resistance After Modest GainNew Highs New Lows - The Legal Advocate
Trevi Therapeutics (TRVI) Shows Potential as Shares Climb Over 2%OBV Divergence - thelegaladvocate.com
Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation - MSN
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN
TRVI Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Shares Edge HigherRevenue Inflection Point - thelegaladvocate.com
Trevi Therapeutics Q1 2026 Earnings: Narrowing Losses but Trial Failures Weigh on SentimentPost-Announcement Reaction - The Legal Advocate
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow
TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus
Trevi Therapeutics (TRVI) Q1 2026 Disappoints — EPS $-0.09 Below $-0.08 ViewsSpecial Dividend Alert - newsline.com
Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS
Trevi Therapeutics (TRVI) Q1 2026 Earnings: Miss Sparks ConcernProfit Margin Analysis - thelegaladvocate.com
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):